Brisbane, Australia and Carlsbad, CA – ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into agreements to establish a Medical Advisory Board to advise the Company on the design of clinical trials for the use of bioimpedance…
Medical Advisory Board per la cronica insufficienza cardiaca Fondata
Brisbane, Australia e Carlsbad, CA – ImpediMed Limited (ASX: IPD) un fornitore globale di tecnologia medica di misurare, controllare e gestire lo stato liquido e la composizione corporea, ha annunciato oggi di aver stipulato accordi per stabilire una Medical Advisory Board di consigliare la Società sulla progettazione di studi clinici per l’uso della spettroscopia bioimpedenza…
ImpediMed Announces U.S. Commercial Launch of L-Dex® System for Assessment of Lymphedema in Cancer Survivors
CARLSBAD, CA, January 7, 2016 – ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex® system to aid in the clinical assessment of lymphedema. This follows a successful pilot program involving six U.S. cancer centers, a…
ImpediMed annuncia US lancio commerciale di L-Dex® sistema per la valutazione del linfedema nei sopravvissuti al cancro
CARLSBAD, CA, 7 GENNAIO 2016 – ImpediMed Limited (ASX: IPD), fornitore globale di tecnologia medica di misurare, controllare e gestire lo stato idrica in pazienti, ha annunciato il lancio commerciale degli Stati Uniti del suo sistema L-Dex® per aiutare nella la valutazione clinica del linfedema. Questo segue un programma pilota di successo che coinvolge sei…
Lymphoedema included in ACS/ASCO Breast Cancer Survivorship Care Guideline
Brisbane, Australia – ImpediMed (ASX: IPD) is pleased to announce that the first joint American Cancer Society (ACS)/American Society of Clinical Oncology (ASCO) Breast Cancer Survivorship Care Guideline has now been published in the Journal of Clinical Oncology. The guideline recommends clinicians to focus on the early identification and management of lymphoedema and counsel survivors…
Linfedema incluso in ACS / ASCO Breast Cancer Survivorship Cura Guideline
Brisbane, Australia – ImpediMed (ASX: IPD) è lieta di annunciare che il primo giunto American Cancer Society (ACS) / American Society of Clinical Oncology (ASCO) Breast Cancer Survivorship Cura Direttiva è stata ora pubblicata sul Journal of Clinical Oncology. La linea guida raccomanda ai medici di concentrarsi sulla individuazione precoce e la gestione del linfedema…
Harvard Clinical Research Institute Agreement
Brisbane, Australia – ImpediMed Limited (ASX: IPD) a leading provider of technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into an agreement with the prestigious Harvard Clinical Research Institute (HCRI) located in Boston, Massachusetts, to advance research around the use of bioimpedance spectroscopy (BIS) in fluid…
Harvard Clinical Research Institute Accordo
Brisbane, Australia – ImpediMed Limited (ASX: IPD), un fornitore leader di tecnologia per misurare, monitorare e gestire lo stato liquido e la composizione corporea, ha annunciato oggi di aver stipulato un accordo con la prestigiosa Harvard Clinical Research Institute (HCRI) che si trova a Boston , Massachusetts, per far avanzare la ricerca intorno all’uso della…
ImpediMed Announces Purchase of Key Assets and Intellectual Property
Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“The Company”), a leading provider of technology to measure, monitor and manage fluid status and body composition, today announced that it has acquired certain key assets and intellectual property from Intersection Medical Incorporated. The purchase includes all rights, title, and interest in bioimpedance spectroscopy and other associated technology…
ImpediMed annuncia acquisti di attività chiave e proprietà intellettuale
Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“The Company”), a leading provider of technology to measure, monitor and manage fluid status and body composition, today announced that it has acquired certain key assets and intellectual property from Intersection Medical Incorporated. The purchase includes all rights, title, and interest in bioimpedance spectroscopy and other associated technology…